Xcout Intel
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Subscribe to see Entrada Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Entrada Therapeutics, Inc. at a glance
Entrada Therapeutics, Inc. is a biotech company headquartered in Boston, United States. It is publicly listed (TRDA) with a market capitalisation of $187.7M. Xcout tracks 16 named people at Entrada Therapeutics, Inc., including Dipal Doshi (Chief Executive Officer & Director). Xcout recorded 19 job postings from Entrada Therapeutics, Inc. in the last 90 days.
Entrada Therapeutics, Inc. leadership
- Dipal DoshiChief Executive Officer & Director
- Natarajan SethuramanPresident of Research & Development
- Nathan J. DowdenPresident & Chief Operating Officer
- Kory James WentworthChief Financial Officer & Treasurer
- Karla MacDonaldChief Corporate Affairs Officer
- Kerry RobertSenior Vice President of People
10 more named people on record for Entrada Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Entrada Therapeutics, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $116.2M | 12 named | |
| Series A | $86.3M | 5 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Hiring at Entrada Therapeutics, Inc.
Xcout recorded 19 job postings from Entrada Therapeutics, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see Entrada Therapeutics, Inc.'s hiring signals →
Investors
Entrada Therapeutics, Inc. competitors
A few of Entrada Therapeutics, Inc.'s closest competitors — see the full list of competitors and alternatives →
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Solid Biosciences Inc. is a precision genetic medicine life science company headquartered in Charlestown, Massachusetts, focused on developing treatments for rare neuromuscular and cardiac diseases.
Aera Therapeutics is a biotechnology company headquartered in Cambridge, Massachusetts, focused on harnessing a proprietary delivery platform to advance genetic medicines.
Edgewise Therapeutics, Inc. is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Dynacure is a biotechnology company developing antisense oligonucleotide therapies for rare neuromuscular diseases. Its lead program, DYN101, targets DNM2-associated centronuclear myopathy for patients with this serious inherited muscle disorder.
Get Entrada Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Entrada Therapeutics, Inc.? Suggest a correction
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Entrada Therapeutics, Inc. in Xcout Intel
- 16 named people with titles, LinkedIn and board committees
- 2 funding rounds before the IPO with the investors in each, and who they co-invest with
- Weekly hiring history and the mix of roles behind it
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access